University of Maryland, Baltimore

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Maryland, Baltimore sits in the top decile of US sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count).

560 total trials 103 currently recruiting 332 completed early-phase tilt top decile by trial count

University of Maryland, Baltimore: 560 sponsored US clinical trials, 103 recruiting.

University of Maryland, Baltimore sponsors 560 registered US clinical trials on ClinicalTrials.gov, 103 of them currently recruiting, and 332 completed. 77 of these trials are in Phase 3-4 (later-stage) and 161 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 14 trials.

Top-decile sponsor footprint

University of Maryland, Baltimore ranks in the top decile of sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 42/100

332 of 410 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

560 total, page 8 of 12

COMPLETED NA

Let's STOP Now Trial: Smoking in Trauma Orthopaedic Patients

NCT02428244

COMPLETED Early Phase 1

Oxytocin, Emotions and Mirror Neurons

NCT02228031

COMPLETED Phase 4

Transdermal Patch CVD 1000: The Effect of Heat on Nicotine Release From Nicotine Patches in Adult Smokers

NCT02371850

COMPLETED NA

Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity

NCT02118610

COMPLETED NA

Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

NCT02420327

COMPLETED Phase 2

Tryptophan MRI in People With Schizophrenia and Healthy Controls

NCT02067975

COMPLETED Phase 4

Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans

NCT04218799

COMPLETED NA

Metabolic Actions of Omega-3 Fatty Acids

NCT01896414

COMPLETED NA

MediHoney for Radiation Dermatitis

NCT02234479

COMPLETED NA

Postoperative Heme Oxygenase Induction and Carbon Monoxide Production as a Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy

NCT04195438

COMPLETED NA

Care Coordination/Home Telehealth to Safeguard Care in CKD

NCT03038126

TERMINATED NA

Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)

NCT01925573

TERMINATED Phase 1

A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis

NCT01954524

COMPLETED

MICRO Study: Detecting Bacterial Infections Related to Orthopaedic Surgical Implants

NCT03132246

COMPLETED

Improving Heart Failure Outcomes Rural

NCT02395588

COMPLETED NA

Biological Evaluation of Dietary Supplement Liposomal Glutathione

NCT01967667

TERMINATED

1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer

NCT02700776

COMPLETED Early Phase 1

Borderline Pancreas Study: FOLFIRINOX +SBRT

NCT01992705

COMPLETED NA

Oxytocin and CBSST for People With Schizophrenia

NCT01752712

TERMINATED Phase 2

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

NCT02000596

COMPLETED

Ultra Coils From Start to Finish for the Endovascular Repair of Small Intracranial Aneurysms

NCT02657772

COMPLETED NA

Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-Positive

NCT01927276

COMPLETED

Tobacco Craving and Triggers in Persons With Schizophrenia

NCT01846065

COMPLETED NA

Neuroendocrine and Immune Response to Stress in Schizophrenia

NCT01975584

COMPLETED NA

MedActive: A Smartphone Intervention to Improve Adherence to Antipsychotic Medications

NCT01953237

COMPLETED Phase 3

Switch to Maraviroc + Integrase Inhibitor

NCT01896921

COMPLETED

4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation

NCT01764659

COMPLETED Phase 2

Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants

NCT01778634

COMPLETED NA

Improving Community Ambulation After Hip Fracture

NCT01783704

TERMINATED NA

Spray Cryotherapy for Esophageal Cancer (ICE-CANCER)

NCT01868139

COMPLETED Phase 2

Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial

NCT01756833

COMPLETED NA

The Family VOICE Study

NCT01804582

TERMINATED Phase 2

Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme

NCT01822275

COMPLETED Phase 1

Intestinal Permeability in Preterm Infants

NCT01756040

TERMINATED NA

Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)

NCT01881932

COMPLETED Phase 1

Impact of Formulation on Ciprofloxacin Oral Absorption

NCT00992329

TERMINATED NA

Early Elimination of Premature Ventricular Contractions in Heart Failure

NCT01757067

TERMINATED NA

Acupuncture in Reducing the Severity of Chemoradiation-induced Mucositis in Patients With Oropharyngeal Cancer

NCT01883908

COMPLETED Early Phase 1

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)

NCT01672255

COMPLETED Phase 1

Pharmacokinetic and Safety Evaluation of L-tetrahydropalmatine (l-THP) With Cocaine Exposure in People With a History of Cocaine Use

NCT01631383

COMPLETED

Breast Cup Immobilization Device II (GCC 1047)

NCT01704547

COMPLETED Phase 3

Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)

NCT01692743

TERMINATED NA

Topiramate for Alcohol Use in Posttraumatic Stress Disorder

NCT01408641

COMPLETED NA

Assessment of End Expiratory Lung Volumes in Healthy Subjects Using High Flow Oxygen (Vapotherm®)

NCT01672242

COMPLETED Phase 1

Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

NCT01650545

COMPLETED Phase 4

Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia

NCT01614093

COMPLETED NA

Anti-Inflammatory Treatment of Schizophrenia

NCT01514682

COMPLETED Phase 4

Lamotrigine Bioequivalence

NCT01995825

TERMINATED Phase 2

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

NCT01499160

COMPLETED NA

Hand Hygiene Before Non-sterile Glove Use

NCT01571778

← Previous Page 8 of 12 Next →

Phase Distribution

PhaseTrial count
Phase 1 82
Phase 2 79
Phase 3 10
Phase 4 67

What is open in the University of Maryland, Baltimore pipeline

103 recruiting of 560 indexed (18% open); 332 completed (59%).

Phase mix: 77 late (III/IV) vs 161 early (I/II) (early-phase heavy).

Top condition: Schizophrenia (14 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Maryland, Baltimore: open-pipeline peers nationwide

Peers matched on 560 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 5%10%15%20%25% Total trials Recruiting share University of Maryland, BaltimoreAmgenMerck Sharp & DohmeVirginia Commonwealth UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Abramson Cancer Center at Penn MedicineHenry Ford Health SystemNew York Institute of TechnologyUniversity of California, San Diego
University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 560 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this University of Maryland, Baltimore page

560 registered trials is a research-attention snapshot, not an endorsement of University of Maryland, Baltimore or any single study.

  • 103 of University of Maryland, Baltimore's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Schizophrenia is the condition University of Maryland, Baltimore studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Maryland, Baltimore pipeline card: 560 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.